02 November 2020>: Lab/In Vitro Research
Detecting Rare Variants and Heteroplasmy of Mitochondrial DNA from High-Throughput Sequencing in Patients with Coronary Artery Disease
Qian Jia 12ABE* , Lu Xu 1CE* , Juan Shen 3CD , Yanping Wei 3CD , Huaiqian Xu 3B , Jionglong Shi 24D , Zhilong Jia 24D , Xiaojing Zhao 12D , Chunlei Liu 12D , Qin Zhong 12F , Yaping Tian 1AD* , Kunlun He 12A*DOI: 10.12659/MSM.925401
Med Sci Monit 2020; 26:e925401
Figure 3 The non-synonymous heteroplasmy counts differed between cases and controls in both stages. We split heterogeneity sites into 3 groups according to the percentage of samples carrying one heterogeneity sites: the percentage >0% (A1, B1, C1), >2% (A2, B2, C2), and >5% (A3, B3, C3). For each group, the Wilcox statistic was used to test the heteroplasmy counts difference. The ratio was calculated as the mean count of heteroplasmic sites in cases divided by the mean -count of heteroplasmic sites in controls.